BUND FINANCE › Stocks › GMAB
Genmab A/S (GMAB)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +21.70% above its 50-day average.
- It is +60.65% above its 200-day average (long-term uptrend).
- It sits at 77% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$8.4B | US$14.5B | US$16.5B | US$21.5B | US$3.7B |
| Net income | US$3.0B | US$5.5B | US$4.4B | US$7.8B | US$963.8M |
| EPS (diluted) | 4.48 | 8.26 | 6.60 | 12.14 | 1.54 |
| Gross margin | 100.0% | 100.0% | 98.6% | 95.4% | 91.7% |
| Operating margin | 35.1% | 43.2% | 32.3% | 31.1% | 33.6% |
| Net margin | 35.1% | 37.6% | 26.4% | 36.4% | 25.9% |
| Free cash flow | US$2.0B | US$3.6B | US$7.0B | US$7.6B | US$1.1B |
| Total debt | US$425.0M | US$597.0M | US$770.0M | US$1.0B | US$5.4B |
| Cash | US$9.0B | US$9.9B | US$14.9B | US$9.9B | US$1.7B |
Compound annual growth: revenue -18.5% · net income -24.4% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 43.6x | 31.5x | 27.1x |
| EV / EBITDA | 28.8x | 22.2x | 16.5x |
| Operating margin | 30.6% | — | 3.6% |
| Net margin | 17.0% | — | -0.0% |
| Debt / equity | 1.04 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Genmab A/S
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintai…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice